Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814)

The journal of prevention of Alzheimer's disease

Volumn 4, Issue 4, 2017, Pages 247-254

  Sims, J R ^a   Selzler, K J ^b   Downing, A M ^b   Willis, B A ^b   Aluise, C D ^b   Zimmer, J ^b   Bragg, S ^b   Andersen, S ^b   Ayan Oshodi, M ^b   Liffick, E ^b   Eads, J ^b   Wessels, A M ^b   Monk, S ^b   Schumi, J ^b   Mullen, J ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

Alzheimer s disease; BACE1 inhibitor; Lanabecestat; MCI due to AD; mild AD

Indexed keywords

4-METHOXY-5'-METHYL-6'-(5-(PROP-1-YN-1-YL)PYRIDIN-3-YL)-3'H-DISPIRO(CYCLOHEXANE-1,2'-INDEN-1',2'-IMIDAZOL)-4'-AMINE; AMYLOID PRECURSOR PROTEIN; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; SECRETASE; SPIRO COMPOUND;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; HUMAN; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITIVE DYSFUNCTION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; SPIRO COMPOUNDS;

EID: 85049845384     PISSN: None     EISSN: 24260266     Source Type: Journal    
DOI: 10.14283/jpad.2017.38     Document Type: Review

References (0)